ELOVL5

Across TCGA pan-cancer cohorts, ELOVL5 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of ELOVL5’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where ELOVL5 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ELOVL5 is over-expressed in tumor.

CCRCC, LUAD, and LSCC are the cancer types where ELOVL5 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ELOVL5 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	II,III,IV	+0.335	.001	10	view →
LUAD	Female	III,IV	+0.953	<.001	9	view →
LSCC	Female	All	+0.841	<.001	9	view →
COAD	Female	II,III,IV	+0.844	<.001	8	view →
HNSC	Male	IV	+0.604	<.001	8	view →
PDAC	All	All	+0.364	.016	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

ELOVL5–CCRCC

Open the CCRCC breakdown →